Oral Blood Cancer

SAN DIEGO — Insurers rejected one-third of new prescriptions for specialty oral anticancer medications ordered for patients with blood cancers, according to retrospective data presented at ASH Annual Meeting and Exposition. Patients with commercial insurance and Medicaid had prescriptions rejected more often than patients with Medicare.